[6] BD is ranked #211 in the 2024 Fortune 500 list[7] based on its revenues for the fiscal year ending September 30, 2023.

[20] Pfitzer et al. (2013) identify BD's development of a needleless injection system as an example of leading businesses' role in creating shared value.

They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations.

Bard, Inc. and its parent company BD were fined $60 million USD for failing to adequately inform patients about health risks related to their transvaginal mesh devices.

BD recalled and tested the syringes in question, and revealed sterile particulates in 0.013 percent of the products.

BD stated that the use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death.

The recall was initiated on Oct. 28, 2009 after BD received complaints of problems due to air entry through a part of the device.

[26] In March 2021 BD announced a recall of infusion sets for CC, GP, VP, GW/GW800, SE, and IVAC 590 Alaris Pumps and gravity infusion sets and connectors following the news that a supplier falsified sterilisation documents going back ten years.